China investors step up focus on medtech, healthcare services
This article was originally published in Clinica
Medical devices, clinical services and mHealth technology took a significant chunk of the near-$2m that went into healthcare-related investment in China last year, according to Zero2IPO, a local private equity fund. While pharmaceuticals still accounted for 46% of total M&A investment, medical devices came second with 33% and health services made up the remainder.
You may also be interested in...
A regulatory framework that encourages physicians to conduct experimental cell and gene therapies have propelled China to become a major developer of such promising cancer-treating tools, but insiders say three are a plethora issues at stake.
Prices of direct acting hepatitis C drugs are down by 85% in China, with cancer and antidiabetes therapy costs cut by 65% and drug makers are rushing to celebrate. Scrip delves into the considerations behind the low prices and whether industry's excitement is a bit premature.
Rapid changes in China prompt many pharma companies to shuffle strategies and accelerate personal changes. BMS is getting a new country GM, Pfizer Biopharma China GM is departing and Takeda BU head is stepping down.